抗HIV治療ガイドライン（2023年3月発行）

XV小児、青少年期における抗HIV療法

文献

  1. Guidelines for the use of antiretroviral agents in pediatric HIV infection. (米国 DHHS Jan. 31, 2023) . https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new
  2. PENTA HIV FIRST AND SECOND LINE ANTIRETROVIRAL TREATMENT GUIDELINES 2019
    https://penta-id.org/hiv/treatment-guidelines/
  3. European AIDS Clinical Society (EACS) Guidelines. Version 11.1-October 2022. https://eacs.sanfordguide.com/
  4. Dunn DT, Brandt CD, Kirvine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intrapartum transmission. AIDS. 9: F7-11. 1995.
  5. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 160(1):60-6. 2012.
  6. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR. 58[RR-11]:1-166. 2009.
  7. HIV Paediatric Prognostic Markers Collaborative Study, Boyd K, Dunn DT, et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS. 24(8):1213-17. 2010.
  8. Centers for Disease Control and Prevention: Revised Surveillance Case Definition for HIV Infection-United States, 2014. MMWR 63(No. RR-3):1-10. 2014.
  9. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 336:1337-42. 1997
  10. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and longterm mortality risk in HIV-1-infected children. J Infect Dis. 175:1029-38. 1997.
  11. Palumbo PE, Raskino C, Ficus S, et al. Predictive value of quantitative plasma RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 279:756-61. 1998.
  12. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 350:2471-80. 2004.
  13. Clarke DF, Penazzato M, Capparelli E, et al. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol.2018;11(1):83-93.
  14. Laughton B, Cornell M, Grove D et al.: Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 26 :1685-90. 2012.
  15. HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 362:1605-11.2003.
  16. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 359:2233-44. 2008.
  17. Goetghebuer T, Haelterman E, Le Chenadec J, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009. 23: 597-604.
  18. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 382:1555-63. 2013.
  19. Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis. 12(12):933-41. 2012.
  20. Szubert AJ, Musiime V, Bwakura-Dangarembizi M, et al. Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS. 29(5):609-18. 2015.
  21. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial-PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses. 16:1113-21. 2004.
  22. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection F-25 Antimicrob Agents Chemother. 2016;60(12):7086-7097. Available at: https://pubmed.ncbi.nlm.nih.gov/27645238/
  23. Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12):e01695-01617.
  24. Neogi U, Singh K, Aralaguppe SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS.2018;32(4):469-476.
  25. Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patientderived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56.
  26. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 366(25):2380-9. 2012.
  27. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 23:1097-107. 2009.
  28. Tannner JM: Growth at Adolescence. Ed 2. Oxford Blackwell Scientific Publications, 1962.
  29. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 119:e1371-83. 2007.

PAGE TOP